IMMUNOGENETIC FACTORS IN THE PROGNOSIS OF HIV INFECTIONS

HIV 感染预后中的免疫遗传因素

• 批准号: 3142408
• 负责人: MARILYN S POLLACK
• 金额: $ 16.34万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-09-30 至 1992-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3142408
• 关键词: HIV infections; Kaposi's sarcoma; antibody; antiviral antibody; cell membrane; complement; concanavalin A; gene expression; helper T lymphocyte; histocompatibility antigens; human subject; immunogenetics; mitogens; opportunistic infections; prognosis; ribavirin; sign /symptom; suppressor T lymphocyte

Since infection with the virus causing Acquired Immunodeficiency Syndrome (AIDS), HIV, as detected by the presence of specific antibodies to that virus, occurs in an increasing number of individuals who continue to have no or only very preliminary symptoms of actual clinical manifestations of the infection for prolonged periods, immunogenetic factors may contribute to the ability of different individuals to control virus effects. Many such individuals are being monitored in Houston for the possible development of clinical symptoms and signs and some are being treated in experimental protocols designed to evaluate whether or not certain antiviral agents may prevent the development of clinical symptoms and signs and some are being treated in experimental protocols designed to evaluate whether or not certain antiviral agents may prevent the development of clinical signs and/or increase T4 cell counts. Various studies indicate that some of these antibody positive individuals will develop clinical manifestations of the immunodeficiency syndrome each year. They also suggest that genetic and immunological parameters that may predict which clinical manifestations (i.e., Kaposi's sarcoma vs opportunistic infections) they might develop include histocompatibility type, complement allotype, cell surface phenotype profile, and in vitro immune function responses. The specific purpose of this project will be to collect histocompatibility, complement allotype, cell surface phenotype and immune function data for a large group of individuals with antibodies to HIV and to correlate these genetic/immune response factors to clinical course including responses to various prophylatic drug treatment protocols. Patients at all stages of possible responses to infection will be recruited as long as information is available as to the approximate likely data of initial infection or first appearance of antibody. Approximately 150 patients per year will be recruited for the study. Cell surface phenotype, including percentage of cells with T4 and T8 and dual staining T8-Leu 7, T8-T10, and T8-Dr, and relative immune responses to PHA, con A, pokeweed mitogen and allogeneic cells, will be assessed at least 3 times per year for each patient. Data from clinical studies relating to skin test responses will also be incorporated into the analyses.

由于感染导致获得性免疫缺陷综合症的病毒 （艾滋病）、艾滋病毒，通过特定抗体的存在来检测 病毒，发生在越来越多的人中，他们继续患有 没有或只有非常初步的实际临床表现症状 长时间感染，免疫遗传因素可能会导致 不同个体控制病毒影响的能力。许多 休斯顿正在对这些人进行监控，以防止可能发生的情况 出现临床症状和体征，有些正在接受治疗 旨在评估是否某些特定的实验方案 抗病毒药物可以预防临床症状的发展 迹象和一些正在接受旨在治疗的实验方案 评估某些抗病毒药物是否可以预防 出现临床症状和/或增加 T4 细胞计数。各种各样的 研究表明，其中一些抗体呈阳性的人会 出现免疫缺陷综合征的临床表现 年。他们还表明，遗传和免疫学参数 可以预测哪些临床表现（即卡波西肉瘤与 他们可能发生的机会性感染包括组织相容性 类型、补体同种异型、细胞表面表型谱和体外 免疫功能反应。 该项目的具体目的是收集 组织相容性、补体同种异型、细胞表面表型和 一大群具有抗体的个体的免疫功能数据 HIV 并将这些遗传/免疫反应因素与临床相关联 课程包括对各种预防性药物治疗的反应 协议。处于对感染可能产生反应的各个阶段的患者将 只要有关于大约的信息，就可以招募 初次感染或抗体首次出现的可能数据。 每年将招募大约 150 名患者参与该研究。细胞 表面表型，包括具有 T4 和 T8 以及双重细胞的百分比 T8-Leu 7、T8-T10 和 T8-Dr 染色以及相对免疫反应 PHA、con A、美洲商陆有丝分裂原和同种异体细胞将在 每个患者每年至少 3 次。临床研究数据 与皮肤测试反应相关的内容也将纳入 分析。